HLB to absorb HLB Life Science in all-stock merger to unify rivoceranib rights
HLB will take over its 17-percent-owned affiliate to consolidate the cancer drug's development and revenue rights under one company, issuing 8.674 million new shares.

HLB said Thursday it will absorb HLB Life Science in an all-stock merger aimed at consolidating the rights and revenue structure for its cancer drug rivoceranib and simplifying its corporate governance.
The merger ratio is 0.09, under which HLB will issue 8,674,057 new shares to HLB Life Science shareholders, amounting to 6.5 percent of HLB's shares outstanding after the deal. HLB valued its own shares at 30,063 won ($23) apiece and HLB Life Science at 2,578 won ($2), putting the surviving company's corporate value at 4.01 trillion won ($3.01 billion) and the dissolving company's at 314 billion won ($236 million). HLB currently owns 17 percent of HLB Life Science, or 20,695,725 shares.
Consolidating HLB Life Science's exclusive domestic development and sales rights for rivoceranib, along with its revenue participation rights in Japan and Europe, into HLB will simplify the drug's rights structure. A company official said the merger is a strategic decision to build a management system optimized for commercializing new drugs by combining the two companies' drug development capabilities and business foundations.
HLB attempted the same merger last year but withdrew it after shareholder buyback demands exceeded a 40 billion won ($30.1 million) termination threshold set in the merger agreement. It is reviving the plan as commercialization of the drug gathers pace.
Both companies set up special committees of three independent directors each to review the merger's feasibility and the fairness of its terms through outside expert advice and valuation, and they are running shareholder meetings and a question-and-answer channel on their website.
HLB plans to use the combined entity to step up cross-selling by linking HLB Life Science's medical consumables business, including syringes, with HLB's healthcare business and distribution network, and to pool research and development staff and resources.
What this article is based on
Every fact in this article can be checked against the primary documents below.
- Regulatory filingHLB 주요사항보고서(회사합병결정)· DART· accessed Nov. 20, 2026
- Other주력 사업· hlbkorea.com· accessed Nov. 20, 2026
- Other임상 데이터· hlbkorea.com· accessed Nov. 20, 2026
- Other합병 절차 — 주주 보호 장치· hlbkorea.com· accessed Nov. 20, 2026
© New Era Korea Daily. All rights reserved.
More in Companies
- Kumho Engineering wins 145 billion won rail contract in North Gyeongsang
- L&F raises 30.3 billion won in perpetual convertible bonds for cathode expansion
- Meritz Financial third-quarter revenue jumps 78% as net income slips
- Phionx to raise 13.6 billion won via rights issue and convertible bonds
- Samsung Heavy Industries wins 342 billion won LNG carrier order